Standard peritoneal dialysis (PD) solutions contain high levels of glucose and glucose degradation products (GDPs), both contributing to the formation of advanced glycation end products (AGEs). We studied the contribution to plasma GDP and AGE levels of 2 PD regimens that differ in glucose and GDP loads: high load [standard PD (sPD) using 4 glucose-lactate exchanges] and low load [1 amino acid exchange, 1 icodextrin exchange, and 2 glucose-bicarbonate/lactate exchanges (“NEPP”)].
Methods
In a prospective crossover study (2 periods of 24 weeks), new continuous ambulatory PD patients were randomized to NEPP-sPD (n = 23) or to sPD-NEPP (n = 27).
Results
After the start of PD, absolute increases were observed in plasma levels of 3-deoxyglucosone (3-DG, 220.4 nmol/L, p < 0.0001) and in Nε-(carboxymethyl) lysine (CML) in plasma proteins (0.02 μmol/L CML per 1 mol/L lysine, p < 0.0001). During the first 6 weeks, 3-DG tended to increase more with sPD treatment (p = 0.08), and CML, with NEPP treatment (p = 0.002). In both groups, Nε-(carboxyethyl)lysine (CEL) in plasma proteins declined significantly with the start of PD. Treatment with NEPP resulted in higher levels of methylglyoxal (MGO) and lower levels of 3-DG and CEL. Pentosidine in the albumin fraction tended to increase less during NEPP treatment.
Conclusions
A low glucose and GDP PD regimen (NEPP) resulted in plasma levels of 3-DG and CEL that were lower than those with a glucose-based sPD regimen. Starting PD with NEPP was associated with a steeper increase in CML, and continuing treatment with NEPP resulted in higher MGO levels.
FoleyR.N., ParfreyP.S., SarnakM.J.Clinical epidemiology of cardiovascular disease in chronic renal disease.Am J Kidney Dis1998; 32(Suppl 3): S112–19.
4.
LongeneckerJ.C., CoreshJ., PoweN.R., LeveyA.S., FinkN.E., MartinA.Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study.J Am Soc Nephrol2002; 13: 1918–27.
5.
SulimanM.E., HeimbürgerO., BárányP., AnderstamB., Pecoits-FilhoR., Rodríguez AyalaE.Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy.J Am Soc Nephrol2003; 14: 1614–22.
6.
BrownleeM.Advanced protein glycosylation in diabetes and aging.Annu Rev Med1995; 46: 223–34.
7.
SchalkwijkC.G., PosthumaN., ten BrinkH.J., ter WeeP.M., TeerlinkT.Induction of 1,2-dicarbonyl compounds, intermediates in the formation of advanced glycation end-products, during heat-sterilization of glucose-based peritoneal dialysis fluids.Perit Dial Int1999; 19: 325–33.
8.
MiyataT., DevuystO., KurokawaK., van Ypersele de StrihouC.Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes.Kidney Int2002; 61: 375–86.
9.
MiyataT., UedaY., ShinzatoT., IidaY., TanakaS., KurokawaK.Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: renal implications in the pathophysiology of pentosidine.J Am Soc Nephrol1996; 7: 1198–206.
10.
NakayamaM., KawaguchiY., YamadaK., HasegawaT., TakazoeK., KatohN.Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD.Kidney Int1997; 51: 182–6.
11.
ErixonM., WieslanderA., LindénT., CarlssonO., JönssonJ.A., SimonsenO.3,4-Dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma.Perit Dial Int2009; 29(Suppl 2): S28–31.
12.
ErixonM., WieslanderA., LindénT., CarlssonO., JönssonJ.A., SimonsenO.3,4-DGE in peritoneal dialysis fluids cannot be found in plasma after infusion into the peritoneal cavity.Perit Dial Int2008; 28: 277–82.
13.
ZeierM., SchwengerV., DeppischR., HaugU., WeigelK., BahnerU.Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation?Kidney Int2003; 63: 298–305.
14.
MiyataT., KurokawaK., van Ypersele de StrihouC.Advanced glycation and lipoxidation end products: role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism.J Am Soc Nephrol2000; 11: 1744–52.
15.
SchalkwijkC.G., ter WeeP.M., TeerlinkT.Reduced 1,2-dicarbonyl compounds in bicarbonate/lactate-buffered peritoneal dialysis (PD) fluids and PD fluids based on glucose polymers or amino acids.Perit Dial Int2000; 20: 796–8.
16.
le PooleC.Y., van IttersumF.J., WeijmerM.C., ValentijnR.M., ter WeeP.M.Clinical effects of a peritoneal dialysis regimen low in glucose in new peritoneal dialysis patients: a randomized crossover study.Adv Perit Dial2004; 20: 170–6.
17.
le PooleC.Y., van IttersumF.J., WeijmerM.C., ValentijnR.M., ter WeeP.M.Clinical effects of a PD regimen low in glucose in new PD patients: a randomized cross-over study.Perit Dial Int2005; 25(Suppl 3): S64–7.
18.
OdettiP., FogartyJ., SellD.R., MonnierV.M.Chromatographic quantitation of plasma and erythrocyte pentosidine in diabetic and uremic subjects.Diabetes1992; 41: 153–9.
19.
MiyataT., van Ypersele de StrihouC., KurokawaK., BaynesJ.W.Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications.Kidney Int1999; 55: 389–99.
20.
WilkerS.C., ChellanP., ArnoldB.M., NagarajR.H.Chromatographic quantification of argpyrimidine, a methylglyoxal-derived product in tissue proteins: comparison with pentosidine.Anal Biochem2001; 290: 353–8.
21.
FriedlanderM.A., WuY.C., ElgawishA., MonnierV.M.Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal dialysis.J Clin Invest1996; 97: 728–35.
22.
InagiR., MiyataT.Oxidative protein damage with carbohydrates and lipids in uremia: “carbonyl stress.”Blood Purif1999; 17: 95–8.
23.
TeerlinkT., BartoR., Ten BrinkH.J., SchalkwijkC.G.Measurement of Nε-(carboxymethyl)lysine and Nε-(carboxyethyl) lysine in human plasma protein by stable-isotope-dilution tandem mass spectrometry.Clin Chem2004; 50: 1222–8.
24.
TwiskJ.W.Longitudinal data analysis. A comparison between generalized estimating equations and random coefficient analysis.Eur J Epidemiol2004; 19: 769–76.
25.
MartisL., PatelM., GiertychJ., MongovenJ., TaminneM., PerrierM.A.Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution.Lancet2005; 365: 588–94.
26.
BoerW.H., VosP.F., FierenM.W.Culture-negative peritonitis associated with the use of icodextrin-containing dialysate in twelve patients treated with peritoneal dialysis.Perit Dial Int2003; 23: 33–8.
27.
ThornalleyP.J., Yurek-GeorgeA., ArgirovO.K.Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal, and 3-deoxyglucosone under physiological conditions.Biochem Pharmacol2000; 60: 55–65.
28.
KoningsC.J., SchalkwijkC.G., van der SandeF.M., LeunissenK.M., KoomanJ.P.Influence of icodextrin on plasma and dialysate levels of Nε-(carboxymethyl)lysine and Nε-(carboxyethyl)lysine.Perit Dial Int2005; 25: 591–5.
29.
AhmedM.U., Brinkmann FryeE., DegenhardtT.P., ThorpeS.R., BaynesJ.W.Nε-(Carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins.Biochem J1997; 324: 565–70.
30.
van de KerkhofJ., SchalkwijkC.G., KoningsC.J., CheriexE.C., van der SandeF.M., SchefferP.G.Nε-(Carboxymethyl) lysine, Nε-(carboxyethyl)lysine and vascular cell adhesion molecule-1 (VCAM-1) in relation to peritoneal glucose prescription and residual renal function; a study in peritoneal dialysis patients.Nephrol Dial Transplant2004; 19: 910–16.
31.
UedaY., MiyataT., GoffinE., YoshinoA., InagiR., IshibashiY.Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids.Kidney Int2000; 58: 2518–24.
32.
KusunokiH., MiyataS., OharaT., LiuB.F., UriuharaA., KojimaH.Relation between serum 3-deoxyglucosone and development of diabetic microangiopathy.Diabetes Care2003; 26: 1889–94.
33.
MonnierV.M., VishwanathV., FrankK.E., ElmetsC.A., DauchotP., KohnR.R.Relation between complications of type I diabetes mellitus and collagen-linked fluorescence.N Engl J Med1986; 314: 403–8.
34.
BrownleeM., CeramiA., VlassaraH.Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.N Engl J Med1988; 318: 1315–21.
35.
AronsonD.Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes.J Hypertens2003; 21: 3–12.
36.
YanS.F., RamasamyR., NakaY., SchmidtA.M.Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.Circ Res2003; 93: 1159–69.
37.
McIntyreN.J., ChestertonL.J., JohnS.G., JefferiesH.J., BurtonJ.O., TaalM.W.Tissue-advanced glycation end product concentration in dialysis patients.Clin J Am Soc Nephrol2010; 5: 51–5.
38.
SchwedlerS.B., MetzgerT., SchinzelR., WannerC.Advanced glycation end products and mortality in hemodialysis patients.Kidney Int2002; 62: 301–10.
